Medical and Pharmaceutical Sana Biotechnology could offer relief to diabetes type 1 sufferers in the future The study showed that Sana's hypoimmune (HIP) modified pancreatic islet cells could successfully evade the patient's immune system Joseph MortonJanuary 9, 2025
Medical and Pharmaceutical Hoth Therapeutics up over 218% on dermatology breakthrough for cancer patients The biopharma operator's 'HT-001" drug was highly successful in alleviating skin issues caused by a cancer treatment Rowan DunneJanuary 7, 2025
Medical and Pharmaceutical Sagimet Biosciences up 30% on strong clinical stage data Denifanstat received FDA Breakthrough Therapy designation for metabolic dysfunction-associated steatohepatitis Joseph MortonDecember 16, 2024
Health & Wellness New blood test capable of screening for over 50 cancers available in Canada The Galleri test works by analyzing DNA fragments shed by cancer cells into the bloodstream Joseph MortonDecember 5, 2024
Medical and Pharmaceutical Janux Therapeutics soars on clinical trial data for prostate cancer treatment candidate For 63 per cent of patients, the cancer was either reduced or kept from worsening Joseph MortonDecember 3, 2024
Medical and Pharmaceutical Neurogene patient dies in drug trial, stock surges after FDA says ‘use lower dose’ This unfortunate incident occurred during a study on the company's Rett syndrome therapeutic NGN-401 Rowan DunneNovember 22, 2024
Cannabis FDA gives long-awaited green light to veterans cannabis trial for PTSD After 3 years of negotiating, a cannabis smoking study with 320 American vets is about to kick off Rowan DunneNovember 20, 2024
Medical and Pharmaceutical GRAIL uses lung cancer blood test to determine who needs post-surgery therapy most The first patient has been screened with the R&D-stage test in a Phase III study Rowan DunneNovember 19, 2024
Health & Wellness Rani Therapeutics enjoys 50% bump on insider buying spree The company focuses on oral delivery of biologics, and may be benefiting from investor speculation Joseph MortonOctober 15, 2024
Medical and Pharmaceutical Scholar Rock stock skyrockets on successful phase 3 trial results The SAPPHIRE study demonstrated statistically significant and clinically meaningful improvements Joseph MortonOctober 7, 2024